TEL AVIV, Israel, Jan. 24, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has entered into a standby equity purchase agreement (the “SEPA”) with YA II PN, Ltd. (“YA”), a fund managed by Yorkville Advisors Global, LP. Under the terms of SEPA, YA is committed to purchase up to $20 million of the Company’s ordinary shares over the next thirty-six-month period, subject to a beneficial ownership cap of 4.99% of the share capital of the Company. The purchase price of the ordinary shares will be at a 3% discount of the weighted average price of the Company's ordinary shares during the three consecutive trading day period commencing on the trading day of the delivery of an advance notice by the Company.
The Company will have the right in its sole discretion to sell shares to YA from time to time upon the issuance of an advance notice, which has no right to require the Company to sell any shares, following the effectiveness of a registration statement with the Securities and Exchange Commission registering the ordinary shares issuable pursuant to the SEPA and other customary closing conditions.
The Company intends to use the proceeds from the potential offering of the ordinary shares pursuant to the SEPA for working capital and other general corporate purposes.
The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About SciSparc Ltd. (Nasdaq: SPRC):
Recent SPRC News
- SciSparc to Acquire AutoMax • GlobeNewswire Inc. • 04/11/2024 12:15:00 PM
- SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research • GlobeNewswire Inc. • 03/21/2024 12:58:00 PM
- SciSparc Granted Another Patent, Strengthening its Core Technology in Canada • GlobeNewswire Inc. • 03/18/2024 11:29:00 AM
- SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial • GlobeNewswire Inc. • 03/14/2024 12:49:00 PM
- SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure • GlobeNewswire Inc. • 03/12/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 02:00:02 PM
- SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 03/08/2024 12:11:00 PM
- SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe • GlobeNewswire Inc. • 03/07/2024 12:49:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/07/2024 05:15:11 AM
- SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology • GlobeNewswire Inc. • 03/06/2024 09:41:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 02:07:12 PM
- SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing • GlobeNewswire Inc. • 02/29/2024 01:35:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 02/27/2024 09:15:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2024 01:35:07 PM
- SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 09:27:17 PM
- Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2024 09:27:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/29/2024 09:00:11 PM
- SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 01/29/2024 12:18:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 02:05:42 PM
- SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement • GlobeNewswire Inc. • 01/24/2024 12:42:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 11:02:08 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM